Skip to main content

Table 5 Antimicrobial regimens for the treatment of Acinetobacter baumannii bacteremic pneumonia (inappropriate antibiotics)

From: Influence of severity of infection on the effect of appropriate antimicrobial therapy for Acinetobacter baumannii bacteremic pneumonia

Main agents useda,b No. (%) of patients
(n = 185)
APACHE II score, median (IQR)d No. (%) of patients
Combination therapye 14-Day Mortality P-value 28-Day Mortality P-value
Anti-pseudomonas penicillin-based therapy 28 (15.1) 33 (24–39) 3 (10.7) 19 (67.9) .142 22 (78.6) f .077
Anti-pseudomonas cephalosporin-based therapy 36 (19.5) 31 (21–40) 8 (22.2) 17 (47.2) .287 22 (61.1) .710
Carbapenem-based therapy 61 (33.0) 29 (24–38) 11 (18.0) 38 (62.3) .170 45 (73.8) .047
Colistin-based therapy 7 (3.8) 28 (21–30) 7 (100) 3 (42.9) .702 6 (85.7) .425
Tigecycline-based therapy 13 (7.0) 33 (25–39) 10 (76.9) 9 (69.2) .390 10 (76.9) .382
Fluoroquinolone-based therapy 10 (5.4) 28 (20–39) 3 (30.0) 5 (50.0) .737 7 (70.0) 1
Sulbactam-based therapy 10 (5.4) 30 (18–37) 6 (60.0) 5 (50.0) .737 7 (70.0) 1
Carbapenem + colistin-based therapy 3 (1.6) 19, 27, 28 1 (33.3) 0 .088 3 (100) .555
Carbapenem + tigecycline-based therapy 4 (2.2) 27 (22–31) 2 (50.0) 2 (50.0) 1 3 (75.0) 1
Carbapenem + sulbactam-based therapy 5 (2.7) 31 (29–31) 3 (60.0) 3 (60.0) 1 4 (80.0) .655
Colistin + tigecycline-based therapy 2 (1.1) 19, 40 1 (50.0) 1 (50.0) 1 2 (100) .535
Carbapenem + colistin + tigecycline-based therapy 1 (0.5) 19 0 0 .449 1 (100) 1
Antimicrobial regimensc
 Anti-pseudomonas penicillin only 25 (13.5) 33 (24–39)   18 (72.0) .068 20 (80.0) .070
 Anti-pseudomonas cephalosporin only 28 (15.1) 32 (22–41)   14 (50.0) .553 17 (60.0) .714
 Carbapenem + colistin 2 (1.1) 27, 28   0 .200 2 (100.0) .535
 Carbapenem + tigecycline 2 (1.1) 25, 33   1 (50.0) 1 1 (50.0) 1
 Carbapenem + sulbactam 2 (1.1) 31, 40   2 (100) .503 2 (100) .535
 Carbapenem + fluoroquinolone 1 (0.5) 43   1 (100) 1 1(100) 1
 Carbapenem + tigecycline + colistin 1 (0.5) 19   0 .449 1(100) 1
 Tigecycline only 3 (1.6) 30, 33, 38   3 (100) .254 3 (100) .555
 Colistin + tigecycline 1 (0.5) 40   1 (100) 1 1 (100) 1
  1. aAn antimicrobial agent (or antimicrobial agents)-based therapy denotes the corresponding antimicrobial agent(s) alone or in combination with other antimicrobial agent(s)
  2. b“Colistin” denotes intravenous colistin only. Inhaled colistin is not included
  3. cNot in combination with other antimicrobial agents
  4. dIQR, interquartile range. When the case number is less than 4, the APACHE II score for each case is shown
  5. eCombination therapy is defined as administration of more than one antimicrobial agent
  6. fPatients receiving antipseudomonal penicillin therapy had a significantly higher 28-day mortality compared to other antimicrobial therapy after multivariable adjustment